Article Sidebar
Published:
Jul 8, 2013Keywords:
Article Details
The Journal is owned, published, and copyrighted by the Nigerian Medical Association, River state Branch. The copyright of papers published are vested in the journal and the publisher. Open access authors retain the copyrights of their papers, with the work three months after publication simultaneously licensed under a Creative Commons Attribution License (Attribution, Non-Commercial, No Derivatives” 4.0) - (CC BY-NC-ND 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Main Article Content
A Review of Hepatitis C Virus (HCV) and the Current Management of Genotype 1 Chronic HCV Infection
Abstract
Background: Chronic Hepatitis C virus (HCV) is the primary cause of cirrhosis, hepatocellular carcinoma (HCC), and end- stage liver disease. The addition of protease inhibitor with peginterferon alfa and ribavirin (triple therapy) for genotype 1 infected patients, are the current standard of care.
Method: Data was sourced from available journals and internet based search using pubmed, medline and google search.
Results: successful Treatment of Genotype 1 HCV infected patients with protease inhibitor based triple therapy has improved sustained virologic response (SVR) rates and treatment induced clearance of HCV infection.
Conclusion: significant progress in the management of chronic hepatitis C genotype 1 with the introduction of protease inhibitor (PI) in 2011 with peginterferon and ribavirin has optimized sustained virologic response (SVR).
Keywords: Hepatitis C genotype 1; Pegylated Interferon (Peg IFN); Protease inhibitors (PI), Telaprevir (TVR), Boceprevir (BOC), Ribavirin(RBV).
